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Abstract
Background: Crossover designs are commonly utilised in randomised controlled trials investigating treatments for
long-term chronic illnesses. One problem with this design is its inherent repeated measures necessitate the
availability of an estimate of the within-person standard deviation (SD) to perform a sample size calculation, which
may be rarely available at the design stage of a trial. Interim sample size re-estimation designs can be used to help
alleviate this issue by adapting the sample size mid-way through the trial, using accrued information in a
statistically robust way.
Methods: The AIM HY-INFORM study is part of the Informative Markers in Hypertension (AIM HY) Programme and
comprises two crossover trials, each with a planned recruitment of 600 participants. The objective of the study is to
test whether blood pressure response to first line antihypertensive treatment depends on ethnicity. An interim
analysis is planned to reassess the assumptions of the planned sample size for the study. The aims of this paper are:
(1) to provide a formula for sample size re-estimation in both crossover trials; and (2) to present a simulation study
of the planned interim analysis to investigate alternative within-person SDs to that assumed.
Results: The AIM HY-INFORM protocol sample size calculation fixes the within-person SD to be 8 mmHg, giving >
90% power for a primary treatment effect of 4 mmHg. Using the method developed here and simulating the
interim sample size reassessment, if we were to see a larger within-person SD of 9 mmHg at interim, 640
participants for 90% power 90% of the time in the three-period three-treatment design would be required.
Similarly, in the four-period four-treatment crossover design, 602 participants would be required.
Conclusions: The formulas presented here provide a method for re-estimating the sample size in crossover trials. In
the context of the AIM HY-INFORM study, simulating the interim analysis allows us to explore the results of a
possible increase in the within-person SD from that assumed. Simulations show that without increasing the
planned sample size of 600 participants, we can reasonably still expect to achieve 80% power with a small increase
in the within-person SD from that assumed.
Trial registration: ClinicalTrials.gov, NCT02847338. Registered on 28 July 2016.
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Background
Randomised crossover trials are a well-established design
for long-term chronic illnesses such as hypertension [1].
The UK hypertension NICE guidance (CG127) stratifies
hypertension treatment by age and self-defined ethnicity
(SDE), with guidelines adopting a ‘black versus white’
approach [2]. The problems with this stratification in-
clude a lack of data from UK populations supporting the
current SDE stratification and no reference to South
Asians – the largest ethnic minority group in the UK
[2]. Consequently, the primary objective of the AIM HY-
INFORM study is to determine if the response to exist-
ing first-line antihypertensive drugs differs by ethnic
group, white British, black African/African Caribbean or
South Asian, for participants who are newly diagnosed
or established hypertensives.
The AIM HY-INFORM study comprises two open-
label, randomised crossover trials: one three-period
three-treatment (monotherapy) trial for participants
newly diagnosed with hypertension and one four-period
four-treatment (dual therapy) trial for participants with
existing hypertension. The primary outcome is systolic
blood pressure (SBP) mmHg; linear mixed models are
the preferred method of analysis for a crossover design
with a continuous outcome variable [1]. Repeated mea-
surements of SBP taken from the same participant are
correlated and this correlation needs to be accounted for
in sample size calculations. That is, sample size estima-
tion for any repeated measures design requires an esti-
mate of the within-person standard deviation (SD).
Taking estimates of the within-person SD from other
studies can be unreliable due to differences in the study
population and participant attributes, instruments and
measurement techniques, or other background condi-
tions, which can result in trials that are either under or
over-powered [3, 4]. With the absence of reliable prior
estimates of the within-person SD available for the AIM-
HY INFORM study, in particular for South Asian eth-
nicities, the calculation of the required sample size to
ensure the desired power to detect a single treatment-
by-ethnic interaction is challenging.
To address this issue in many repeated measures con-
texts, sample size re-estimation designs have been con-
sidered [3, 5–7]. However, there is little, directly
applicable work on sample size re-estimation at interim
for crossover designs. Zucker and Denne describe a
strategy to deal with the unknown within-person SD in a
two-stage, repeated measures design that examines the
accrued data at an interim point, obtaining an estimate
of the within-person SD. They then use this estimate to
update the covariance parameter in the linear mixed
model and modify the sample size required to ensure
the trial has sufficient power [3]. Moreover, a collection
of papers have addressed sample size re-estimation in
bioequivalence trials using a two-period two-treatment
crossover design [8–11]. While more recently, method-
ology for blinded and unblinded sample size re-
estimation in multi-treatment crossover trials balanced
for period was described [12]. None of these papers,
however, directly allows for re-estimation in the context
of the AIM HY-INFORM study, for reasons that will be
described shortly.
Here, we present the framework for sample size re-
estimation in both our 3 × 3 (monotherapy) and 4 × 4
(dual therapy) settings. Precisely, the study design and
models used are described, along with the methods de-
veloped for re-estimation of the required sample size.
The planned interim analysis in the AIM HY-INFORM
study states in the protocol that after 50 individuals have
completed their treatment sequence, the sample size cal-
culation for both the mono and dual-therapy treatment
rotations will be recalculated using a mid-trial estimate
of the within-person SD. Therefore, following our initial
descriptions, results from a simulation study carried out
ahead of trial recruitment, with the aim of simulating
the interim analysis to explore the effect of a larger
within-person SD from that assumed in the protocol are
presented.
Methods
Study design
AIM HY-INFORM is a multicentre, prospective study
comprising two randomised, open-label crossover trials
(three-period three-treatment monotherapy and four-
period four-treatment dual therapy) in a multi-ethnic
cohort of hypertensive participants, where each study re-
quires separate randomisation to treatment sequences
[2].
Participants on both trials self-identify into one of the
following three ethnic groups (SDE):
 White (white British, white Irish or any other white
background);
 Black or black British (black Caribbean, black
African or any other black background);
 Asian or Asian British (Asian Indian, Asian
Pakistani, Asian Bangladeshi or any other South
Asian background).
The monotherapy study is a 24-week three-period
three-treatment crossover trial of newly diagnosed hy-
pertensives with Ambulatory Blood Pressure Monitoring
(ABPM) ≥ 135/85 mmHg. After initial screening and
baseline measurement collection, participants are rando-
mised with equal allocation to one of six sequences of
treatments from two three-period three-treatment Latin
square designs: ABC; ACB; BAC; BCA; CAB; and CBA
[13]. Here, treatment A is 1–2 weeks of Amlodipine 5
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mg followed by 6 –7 weeks of Amlodipine 10 mg, treat-
ment B is 1–2 weeks of Lisinopril 10 mg followed by 6–
7 weeks of Lisinopril 20 mg and treatment C is approxi-
mately eight weeks of 25 mg Chlortalidone (Fig. 1).
The dual-therapy study is a 32-week four-period four-
treatment crossover trial of established hypertensives
with ABPM > 135/85 and < 200/110. After initial screen-
ing and baseline measurement collection, participants
are randomised with equal allocation to one of four se-
quences of treatments from a four-treatment four-period
Williams square design: ABDC; BCAD; CDBA; and
DACB. There are 24 possible Latin squares for a four-
treatment crossover design; the design used here is one
of six special cases of the Latin square design which are
balanced for first-order carry-over and are known as
Williams Squares [13, 14].
For participants on dual therapy, treatment A is eight
weeks of Amlodipine 5 mg and Lisinopril 20 mg, treat-
ment B is eight weeks of Amlodipine 5 mg and Chlortali-
done 25mg, treatment C is eight weeks of Lisinopril 20
mg and Chlortalidone 25 mg and treatment D is eight
weeks of Amiloride 10 mg and Chlortalidone 25 mg
(Fig. 2).
The two randomised crossover trials (monotherapy
and dual therapy) are open-label and require separate
randomisation to treatment sequence. To control for
balance permuted blocks within strata are implemented
with an allocation ratio: 1:1:1:1:1:1 for the monotherapy
trial and 1:1:1:1 for the dual-therapy trial.
The monotherapy and dual-therapy trials are distinct
and analysed using separate linear mixed models. The
primary outcome of both trials is seated automated of-
fice SBP mmHg as measured eight weeks (± 4 days) after
receiving each treatment. The primary objective of the
trials is to test for a significant treatment-by-ethnic
group interaction.
With the absence of an available estimate of the
within-participant SD for the trial participants, the
protocol estimates a sample size of 600 participants as-
suming a fixed within-person SD of 8 mmHg, based on
previous clinical trial data in people representative of the
general population with either high normal blood pres-
sure or mild hypertension [2]. More precisely, for a
within-person SD of 8mmHg and a single treatment-by-
ethnic interaction of 3 mmHg, with all other interactions
being 0mmHg, the protocol outlines that a sample size
of 600 participants produces 81.3% power to detect
treatment-by-ethnic interactions using a global test of
interaction at a 5% significance level. For the same fixed
within-person SD of 8 mmHg and a larger single
Fig. 1 Participants receive each treatment A, B and C; they are
randomised to a treatment sequence according to two three-period
three-treatment Latin square designs: ABC, ACB, BAC, BCA, CAB and
CBA, balanced by ethnic group
Fig. 2 Participants receive each treatment A, B, C and D; they are
randomised to a treatment sequence according to a four-period
four-treatment Williams square design: ABDC, BCAD, CDBA and
DACB, balanced by ethnic group
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treatment-by-ethnic interaction of 4 mmHg, a sample
size of 600 participants would give 98% power to detect
a single treatment-by-ethnic interaction. A 10% over-
recruitment allows for loss to follow-up, resulting in 220
planned enrolments from each ethnic group, for each
trial [3].
In order to check the assumptions that the within-
person SD is 8 mmHg, there is a planned interim ana-
lysis after approximately 50 participants have completed
their treatment sequence. The aim of the interim ana-
lysis is twofold: (1) to obtain an estimate of the within
participant SD from trial participants; and (2) to use this
estimate to calculate the sample size required for either
80 or 90% power to detect a treatment-by-ethnic inter-
action using a global test of interaction at a 5% signifi-
cance level. The aim here is to describe the method for
the sample size re-estimation and present results from a
simulation study carried out ahead of the interim
analysis.
Sample size calculations for the protocol along with
simulations, sample size and power calculations for the
interim analysis were carried out using Stata Statistical
Software: Release 14 (StataCorp LP, College Station, TX,
USA).
Models and sample size calculations
Sample size re-estimation in the three-period three-
treatment monotherapy crossover
The linear mixed effects model for the three-period
three-treatment crossover study has fixed effects for
treatment, period, ethnic group and treatment-by-ethnic
group interactions. Additionally, subject is included as a
random effect. This is our unrestricted model. We com-
pare this unrestricted model with a nested restricted
model that does not contain the treatment-by-ethnic
group interaction terms.
Restricted model, assuming n participants are re-
cruited in total:
yijkl ¼ μþ τd j;kð Þ þ π j þ el þ uikl þ ϵijkl:
Unrestricted model:
yijkl ¼ μþ τd j;kð Þ þ π j þ el þ θd j;kð Þl þ uikl þ ϵijkl:
Here
 i = 1, …, n/18 indicates a particular individual, j = 1,
2, 3 indicates the time period, k = 1, …, 6 indicates
the sequence a particular individual was allocated
and l = 1, 2, 3 indicates which of the three
ethnicities a particular individual self-defined as.
That is, i, k and l together completely prescribe a
particular individual in the trial (there are n unique
combinations of these three indices);
 μ is an intercept term (the mean of the values yi1k1);
 τd(j, k) is the direct effect of the treatment
administered to a participant on sequence k in
period j. That is, d(j, k)∈ {A, B, C}. For identifiability
purposes, we set τA = 0;
 πj is a fixed effect for period, with π1 = 0 for
identifiability;
 el is a fixed effect for ethnic group, with e1 = 0 for
identifiability;
 θd(j, k)l is a fixed interaction effect for treatment d(j,
k) by ethnic group l. For identifiability, we set
θA1 = θA2 = θA3 = θB1 = θC1 = 0.
 uikl  N1ð0; σ2bÞ is a random participant effect;
 ϵijkl  N1ð0; σ2eÞ is the residual error.
We perform a global Wald test to see if the unre-
stricted model gives a significantly better fit than the re-
stricted, in order to test the primary hypothesis of
whether there is an interaction between treatment and
ethnic group. To perform sample size re-estimation, we
require the sampling distribution of a suitable test statis-
tic under the null and alternative hypotheses.
Precisely, setting θ = (θB2, θB3, θC2, θC3)
⊤, we test the
following null hypothesis of no treatment-by-ethnic
interactions
H0 : θ ¼ 0;
against the following alternative
H1 : θ≠0:
Denoting by θ^ ¼ ðθ^B2; θ^B3; θ^C2; θ^C3Þ⊤ our estimates of
the interaction terms computed using conventional max-
imum likelihood estimation, we can test H0 using the
following test statistic
t ¼ θ^⊤ dCov θ^ −1θ^:
Moreover, we power our trial for an alternative in
which there is a single non-zero treatment-by-ethnic
interaction (θB2 = δ, i.e. θ = δ = (δ, 0, 0, 0)
⊤).
The complexity of performing a hypothesis test in this
setting, either in a fixed design or following sample size
re-estimation, arises from the fact that the sampling dis-
tribution of T, the random unknown value of t, is in
general complex to compute. Explicitly, while the nu-
merator degrees of freedom in a suitable F-test would be
4, the denominator degrees of freedom is difficult to as-
sign. Kenward and Roger [15] provided a comprehensive
solution to this problem for fixed sample designs by
computing the exact denominator degrees of freedom,
but unfortunately their approach does not lend itself
naturally to sample size re-estimation, as the degrees of
freedom specification procedure is data-dependent.
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Accordingly, Grayling et al. [12] specified the denom-
inator degrees of freedom as that of a corresponding
multi-level single-stage ANOVA design. For our unre-
stricted model this would designate the denominator de-
grees of freedom, ν, for sample size n, as
ν ¼ 3n−n−10 ¼ 2n−10:
Here, the 3n term arises as the total number of mea-
surements accrued, while 1 degree of freedom is sub-
tracted for each participant, and for each fixed effect in
the model. Thus, at the interim we suppose that we
would reject H0 at the end of the trial when t > F
−1(1
− α, 0, 4, 2n − 10), where F−1(q, 0,m, n) is the 100q th
quantile of an F(0, a, b)-distribution (a central F-distribu-
tion on a and b degrees of freedom). Combining this
with a suitable non-central F-distribution under the
chosen alternative at which the trial is to be powered, in-
terim re-estimation can then be performed.
Such an approach, however, was found by Grayling
et al. [12] to, in many circumstances, lead to a notable
inflation of the type-I error rate, and frequently provide
power slightly below the desired level under the speci-
fied alternative. Therefore, they discussed the utility of a
potential α-adjustment procedure, of using the above
methodology for interim re-estimation but performing
the final hypothesis test using the method of Kenward
and Roger [15], and they explored the advantages of a
sample size inflation factor. A problem with these ad-
justments as individual amendments to the basic re-
estimation procedure described above, however, is that
predicting their impact on both the type-I error rate and
the power can be difficult.
Consequently, here, desiring to accurately control the
type-I error rate while maintaining a high level of power,
we make a heuristic conservative adjustment to the
above degrees of freedom based on Hotelling’s T2 distri-
bution [16].
Precisely, for x1, …, xn~Np(ϕ,Ω), the test statistic t2
¼ ðx−ϕÞ⊤dCovðxÞ−1ðx−ϕÞ  T 2ðp; n−1Þ , Hotelling’s T2
distribution on p and n − 1 degrees of freedom. We can
work with this distribution using standard statistical
software via the following relationship
T2 p; n−1ð Þ ¼ p n−1ð Þ
n−p
F p; n−pð Þ:
In our case, we therefore suppose H0 will be rejected
when
2n−13
4 2n−10ð Þ
 
t > F−1 1−α; 4; 2n−13ð Þ:
Moreover, to attain power 1 − β we can search for the
minimal integer n such that
ℙ
2n−13
4 2n−10ð Þ
 
T > F−1 1−α; 4; 2n−13ð Þ
 
≥1−β;
for
T  F δ⊤dCov θ^ −1δ; 4; 2n−13 :
Such a search is easy to perform using interval bisec-
tion over the discrete n. The final problem therefore is
to specify dCovðθ^Þ−1 . In the Appendix, we justify the use
of
dCov θ^  ¼ 12σ^2e
n
1 0:5 0:5 0:25
0:5 1 0:25 0:5
0:5 0:25 1 0:5
0:25 0:5 0:5 1
0BB@
1CCA;
where σ^2e is the interim estimated within person SD,
computed using REML (for the reasons outlined below).
With this, our methodology for re-estimating the required
sample size in the 3 × 3 trial is complete. However, we must
still specify how the final analysis will be performed.
Here, we use REML estimation as it takes into account
the uncertainty in the fixed parameters in the model into
account when estimating the random parameters, in the-
ory leading to better estimates of the variance components
with reduced bias when the number of groups is small
[17]. Additionally, we use the Kenward–Roger approxima-
tion [15] to compute the denominator degrees of freedom
in the final F-test. These choices are again made in order
to limit the possibility of observing inflation to the type-I
error rate. As AIM HY-INFORM is a confirmatory trial of
treatment differences between different ethnic groups, in-
flation of the type-I errors should be avoided.
Sample size re-estimation in the four-period four-treatment
dual-therapy crossover
The dual-therapy trial is a four-period four-treatment
crossover. It will compare the same restricted and unre-
stricted models as for the three-period three-treatment
monotherapy trial. However, we now have
 i = 1, …, n/12, j = 1, …, 4, k = 1, …, 4, and l = 1, 2, 3;
 d(j, k)∈ {A, B, C,D};
 For identifiability, we set
θA1 = θA2 = θA3 = θB1 = θC1 = θD1 = 0.
Here, setting θ = (θB2, θB3, θC2, θC3, θD2, θD3)
⊤, we again
test the following hypotheses
H0 : θ ¼ 0;H1 : θ≠0:
For θ^ ¼ ðθ^B2; θ^B3; θ^C2; θ^C3; θ^D2; θ^D3Þ⊤ our test is once
more based upon
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T ¼ θ^⊤ dCov θ^ −1θ^:
Applying the Hotelling’s T2 based adjustment de-
scribed above, in this case at interim we suppose H0 will
be rejected when
3n−19
6 3n−14ð Þ
 
t > F−1 1−α; 6; 3n−14ð Þ;
and choose the required sample size by determining the
minimal n such that
ℙ
3n−19
6 3n−14ð Þ
 
T > F−1 1−α; 6; 3n−14ð Þ
 
≥1−β;
for
T  F δ⊤dCov θ^ −1δ; 6; 3n−14 ;
with δ = (δ, 0, 0, 0, 0, 0)⊤, and where in the Appendix we
now justify the use of
dCov θ^  ¼ 12σ^2e
n
1 0:5 0:5 0:5 0:25 0:25
0:5 1 0:5 0:25 0:5 0:25
0:5 0:5 1 0:25 0:25 0:5
0:5 0:25 0:25 1 0:5 0:5
0:25 0:5 0:25 0:5 1 0:5
0:25 0:25 0:5 0:5 0:5 1
0BBBBBB@
1CCCCCCA:
Finally, as for the 3 × 3 trial, the final analysis is per-
formed using REML estimation and the Kenward–Roger
correction.
At the interim, 50 participants have completed either
three treatment periods if they are on the monotherapy
trial, or four treatment periods if they are on the dual-
therapy trial. Inherently, we have more data from the
four-treatment crossover and may anticipate better per-
formance in this setting. It is important to note that at
this stage we are not concerned with estimating treat-
ment effects, we simply want the estimate, σ^2e , of the
within-person variance required for the sample size cal-
culations outlined above.
Simulation design
To consider the variation in the estimate of the within-
person SD, a simulation study was carried out to investi-
gate the effect on the requisite final sample size for dif-
ferent treatment effects and within-person SD scenarios,
based on the sample size re-estimation calculations de-
scribed above. In the protocol, the sample size calcula-
tion fixes the SD to be 8 mmHg giving power equal to
98% for a single 4 mmHg interaction effect with 600 par-
ticipants, and 81.3% power with 600 participants and a
single 3 mmHg interaction effect.
Two separate simulation studies have been carried out
assuming participants are on either the monotherapy or
dual-therapy treatment regimes, in all cases assuming
that each participant has received three (monotherapy)
or four (dual-therapy) treatments and that there are no
missing values. Participants are randomly generated with
approximately equal numbers of participants on each of
the six treatment sequences—ABC, ACB, BAC, BCA,
CAB and CBA—for monotherapy and four treatment se-
quences—ABDC, BCAD, CDBA and DACB—for dual
therapy. We consider scenarios in which 80% and 90%
power to detect treatment-by-ethnic interactions are de-
sired, using our outlined global test of interaction at a
5% significance level are assumed.
What is important to realise is that in sample size cal-
culations the within-person SD is typically fixed. In our
simulation study, we set the desired power, the strength
of a single treatment-by-ethnic interaction and a within-
person SD, and solve for sample size across numerous
replicates. Accordingly, of principle interest is the distri-
bution of the interim estimated values of the within-
participant SD and the distribution of the final required
sample sizes.
The factors varied and held constant in these simulations
are outlined in Table 1, resulting in 2 × 2 = 4 scenarios to as-
sess for each of the two trials, with 1000 simulations carried
out for each scenario-trial combination. We assume that
there is no carryover effect and no treatment-by-period
interaction. The between-person SD is held constant at 10
mmHg, we do not need to consider varying this as the pro-
cedures should be invariant to σb with a sample size of 50.
Our methodology for re-estimating the sample size re-
quires a minimum acceptable sample size. In the protocol,
a sample size of 600 is estimated for each monotherapy
and dual-therapy trial, based on a within-person SD of 8
mmHg. As there is no plan to reduce the sample size at
interim, we therefore set a minimum sample size of 600
for all simulations and scenarios investigated. Matlab and
Stata code for sample size calculations can be found in
Additional files 1, 2, 3 and 4.
Results
Simulation of the interim analysis and re-estimation of
the sample size: monotherapy
In the trial protocol, the sample size calculation fixed
the SD to be 8 mmHg, giving > 80% power with 600 par-
ticipants. With simulations, sampling variation means
that we have a range of possible estimates of within-
person SD which means that in this case 90% of the time
640 participants would usually be fine to give us 90%
power to detect the primary effect for a within person
SD of 9 mmHg and a single treatment-by-ethnic inter-
action of 4 mmHg (Fig. 3). A larger within-person SD of
10 mmHg would mean that in 75% of the time 705 par-
ticipants would usually be fine to give us 90% power to
detect the same planned treatment effect (Fig. 3).
Wych et al. Trials          (2019) 20:665 Page 6 of 10
Assuming a smaller single treatment-by-ethnic inter-
action of 3 mmHg, and a 1 mmHg increase in the as-
sumed within-person SD, 75% of the time with a sample
size of 797 participants would give us 80% power to de-
tect the primary hypothesis. A 2 mmHg increase in
within-person SD from that assumed in the protocol
means that 75% of the time with a sample size of 979
participants would give us 80% power detect a treatment
effect of 3 mmHg (Fig. 3). As would be expected, smaller
values of δ, and larger values of σe, imply larger required
sample sizes. Figure 3 shows for the scenario with σe =
9mmHg and δ = 4mmHg more than the planned 600
particpiants are required because of the nature of sample
size re-estimation and the methodology used here. The
conservative approach adopted here to try and control
the type-I error rate means we have to push the sample
size up a little to keep the type-II error rate down. That
is, the use of Kenward–Roger and the Hotelling adjust-
ments pushes the power down compared to the method-
ology used for the initial 600 estimate, so it is inevitable
that the simulations here produce > 600 for the sample
size re-estimation designs.
Simulation of the interim analysis and re-estimation of
the sample size: dual therapy
For the dual-therapy trial, sample sizes required for the
different simulation scenarios are similar to those esti-
mated for the monotherapy trial. For 90% power to
Table 1 Fixed and constant parameter values for the interim analysis simulations
Description Constant factors Factors varied
Interim sample size n = 50
Minimum required sample size n = 600
Number of simulations 1000
Between-person SD σb = 10 mmHg
Within person SD σe = 9, 10 mmHg
Overall mean SBP (mmHg) μ = 140 mmHg
Single treatment-by-ethnic interaction (mmHg) δ = 3, 4 mmHg
Period effect (mmHg) πj = 0 mmHg, ∀j
Power to detect a single ethnic by treatment interaction at 5% significance level (%) 1 − β = 0.1,0.2
Fig. 3 Cumulative density function for re-estimated sample size assuming 80% or 90% power to detect treatment-by-ethnic interactions using a
global test of interaction at the 5% significance level for participants on the monotherapy treatment regime
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detect a treatment effect of 4mmHg, 90% of the time 602
participants would usually be fine when the within-person
SD is 9mmHg. A larger within-person SD of 10mmHg
would mean that 75% of the time 692 participants would
usually be fine to give us 90% power to detect the same
treatment effect (Fig. 4). In both scenarios, the dual-
therapy trial requires slightly fewer participants.
Assuming a smaller single treatment-by-ethnic inter-
action of 3 mmHg, a 1 mmHg increase in the assumed
within-person SD 75% of the time a sample size of 782
participants would give us 80% power to detect the pri-
mary hypothesis. A 2 mmHg increase in within-person
SD from that assumed in the protocol means that 75% of
trials with a sample size of 966 participants would give us
80% power detect a planned treatment effect of 3mmHg;
again, in both scenarios, fewer participants are required
than in the monotherapy trial, as a result of having more
measurements overall in the dual-therapy trial.
In summary, for the same simulated treatment-by-
ethnic interaction an increase in within-person SD re-
quires a large sample size. For the same simulated
within-person SD, a smaller planned treatment effect
also requires a larger sample size, which is what would
be expected from sample size calculation theory. The
fact that the dual-therapy trial when compared with the
monotherapy trial requires slightly fewer participants
when comparing like-for-like is a result of the increased
number of denominator degrees of freedom in the
sample size calculation for the four-period four-
treatment compared with the three-period three-
treatment crossover: 3n – 14 = 136 compared with 2n –
10 = 90 when n = 50. The increased number in the de-
nominator degrees of freedom in the four-period four-
treatment compared with the three-period three-
treatment crossover is in turn due to the increased num-
ber of observations per participant in the four-by-four
crossover trial.
Discussion
A novel method for sample size re-estimation has been
described for three-period three-treatment and four-
period four-treatment crossover trials. Here we have
dealt with a more complicated covariance matrix in a
3 × 3 and 4 × 4 randomised crossover setting that incor-
porates both a global test and allows for interaction
terms in the linear mixed model.
The simulation study allowed us to explore the out-
come for a possible increase in the within-person SD
from that assumed and used for the sample size calcula-
tions in the protocol ahead of trial recruitment and the
interim analysis. As would be expected, an increase in
the within-person SD or a smaller primary treatment ef-
fect would require a larger sample size. The fact that the
dual-therapy trial requires slightly fewer participants
than the monotherapy trial when all variables are like for
like is a consequence of the increased degrees of
Fig. 4 Cumulative density function for re-estimated sample size assuming 80% or 90% power to detect treatment-by-ethnic interactions using a
global test of interaction at the 5% significance level for participants of the dual-therapy treatment regime
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freedom in the denominator of the F-test which is used
in the sample size calculation. The simulation of the in-
terim sample size indicates that we can only realistically
aim for 80% in these scenarios without increasing the
sample size above 600 participants.
Conclusions
The formulas presented here provide a means for re-
estimating the sample size in both three-period three-
treatment and four-period four-treatment crossover tri-
als. In the context of the AIM HY-INFORM study,
simulating the planned interim analysis allows us to ex-
plore the outcome for a possible increase in the within-
person SD from that assumed in the protocol. Simula-
tions show that without increasing the planned sample
size of 600 participants, on each crossover trial, we can
reasonably still expect to achieve 80% power with a small
increased in the within person SD from that assumed.
Appendix
Here, we justify our specified values for dCovðθ^Þ, used in
the sample size re-estimation procedures. To begin, con-
sider the 3 × 3 trial and cast our unrestricted linear
mixed model in the form
Y ¼ Xβþ Zbþ ϵ;
where β = (μ, π2, π3, τB, τC, e2, e3, θB2, θB3, θC2, θC3)
⊤.
Then, the maximum likelihood estimator of the fixed ef-
fects β at the end of trial is
β^¼ μ^; π^2; π^3; τ^B; τ^C ; e^2; e^3; θ^B2; θ^B3; θ^C2; θ^C3
 T
¼ XTΣ−1X 	−1XTΣ−1Y ;
with Σ = ZCov(u)ZT +Cov(ϵ). We then have
Cov β^
 
¼ XTΣ−1X 	−1:
See, for example, Fitzmaurice et al. [18] for further
details.
In our case, CovðuÞ¼σ2bIn and CovðϵÞ¼σ2eI3n: This
implies that Σ is block diagonal, with n blocks of the 3 ×
3 matrix Σ3, say, where
Σ3 ¼
σ2e þ σ2b σ2b σ2b
σ2b σ
2
e þ σ2b σ2b
σ2b σ
2
b σ
2
e þ σ2b
0@ 1A:
It can then be shown by verifying Σ3Σ−13 ¼ I3 that
Σ−13 ¼
1
σ2e σ
2
e þ 3σ2b
 	 σ2e þ 2σ2b −σ2b −σ2b−σ2b σ2e þ 2σ2b −σ2b
−σ2b −σ
2
b σ
2
e þ 2σ2b
0@ 1A:
Now
Cov β^
 
¼ XTΣ−1X 	−1;
¼ n
9
X6
k¼1
X3
l¼1
XTklΣ
−1
3 Xkl
 !−1
;
where Xkl is the design matrix for a single individual
on treatment k, of ethnicity l.
Thus Covðβ^Þ can be found by evaluating the above
expression, which can be readily achieved computation-
ally using a symbolic algebra package. Performing these
calculations in Matlab, and extracting the sub-
component corresponding to θ^, we identified that
Cov θ^
 
¼ 12σ
2
e
n
1 0:5 0:5 0:25
0:5 1 0:25 0:5
0:5 0:25 1 0:5
0:25 0:5 0:5 1
0BB@
1CCA:
It is for this reason that we utilise
dCov θ^  ¼ 12σ^2e
n
1 0:5 0:5 0:25
0:5 1 0:25 0:5
0:5 0:25 1 0:5
0:25 0:5 0:5 1
0BB@
1CCA;
in our re-estimation procedure.
Equivalent calculations for the 4 × 4 trial also demon-
strate that
Cov θ^
 
¼ 12σ
2
e
n
1 0:5 0:5 0:5 0:25 0:25
0:5 1 0:5 0:25 0:5 0:25
0:5 0:5 1 0:25 0:25 0:5
0:5 0:25 0:25 1 0:5 0:5
0:25 0:5 0:25 0:5 1 0:5
0:25 0:25 0:5 0:5 0:5 1
0BBBBBB@
1CCCCCCA:
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